{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:04:57Z","timestamp":1784325897541,"version":"3.55.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate \u226515-letter visual acuity loss after plaque radiotherapy of posterior uveal melanoma (PUM) in the pre\u2013anti\u2013vascular endothelial growth factor era.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We reviewed data on 4,000 consecutive patients managed between 1976 and 2008 regarding patient demographics, tumor features, treatment factors, and \u226515-letter visual acuity loss over time based on tumor size category of small (0\u20133.0 mm thickness), medium (3.1\u20138.0 mm), and large (&gt;8.0 mm).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 4,000 patients, there were small (n = 1,011 eyes, 25%), medium (n = 2,445, 61%), and large (n = 544, 14%) tumor categories. The PUM touched the optic disc (n = 560, 14%) and\/or extended under the foveola (n = 644, 16%). Comparative analysis (small vs. medium versus large PUM) showed small tumor category with demographics of younger age (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01) and greater White race (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05), presenting features of visual acuity \u226520\/40 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01) and closer proximity to the optic disc (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01) and foveola (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01), and radiation treatment parameters most intense at the foveola (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01). The median radiation dose to the optic disc (3,100 vs. 3,257 vs. 4,336 cGy,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01) and the foveola (3,964 vs. 3,864 vs. 4,598 cGy,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01) was noted. Overall, \u226515-letter loss was found in 62% patients at median 16 months. By Kaplan\u2013Meier analysis of all cases, \u226515-letter loss at 1 versus 2 versus 3 versus 5 versus 10 years was present in 30% versus 48% versus 60% versus 73% versus 82%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In the pre\u2013anti\u2013vascular endothelial growth factor days, after treatment of PUM with plaque radiotherapy, visual acuity showed \u226515-letter loss in 62% of patients at median 16 months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004849","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:01:54Z","timestamp":1775484114000},"page":"1363-1370","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["PLAQUE RADIOTHERAPY FOR POSTERIOR UVEAL MELANOMA IN 4000 EYES"],"prefix":"10.1097","volume":"46","author":[{"given":"Carol L.","family":"Shields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidayet","family":"Sener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruba","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Warszawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn G.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oam V.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casen J.","family":"Lockridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Makkithaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis O.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taweevat","family":"Attaseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Lally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry A.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260717","article-title":"Risk factors for 15-letter visual acuity loss from geographic atrophy progression over one year in the age-related eye diseases study 2","author":"Vance","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"R2-20260717","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.survophthal.2005.02.007","article-title":"Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment","volume":"50","author":"Slakter","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"R3-20260717","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41433-024-03520-4","article-title":"Edridge green lecture 2022 \u2013 demystifying clinical trials and regulatory approvals in drug development","volume":"39","author":"Chong","year":"2025","journal-title":"Eye (Lond)"},{"key":"R4-20260717","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/S0161-6420(82)34611-4","article-title":"Radiation retinopathy","volume":"89","author":"Brown","year":"1982","journal-title":"Ophthalmology"},{"key":"R5-20260717","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0161-6420(82)34612-6","article-title":"Radiation optic neuropathy","volume":"89","author":"Brown","year":"1982","journal-title":"Ophthalmology"},{"key":"R6-20260717","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/archopht.118.9.1219","article-title":"Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients","volume":"118","author":"Shields","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R7-20260717","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.ophtha.2009.10.015","article-title":"Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma","volume":"117","author":"Bianciotto","year":"2010","journal-title":"Ophthalmology"},{"key":"R8-20260717","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/IAE.0b013e3182340cc1","article-title":"Vitreous hemorrhage after plaque radiotherapy for uveal melanoma","volume":"32","author":"Bianciotto","year":"2012","journal-title":"Retina"},{"key":"R9-20260717","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0161-6420(00)00526-1","article-title":"Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma I. Visual acuity after 3 years. COMS Report No. 16","volume":"108","year":"2001","journal-title":"Ophthalmology"},{"key":"R10-20260717","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00417-023-06313-9","article-title":"Central subfield thickness predicts visual acuity outcomes in plaque-irradiated eyes with choroidal melanoma","volume":"262","author":"Shah","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R11-20260717","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0161-6420(84)34317-2","article-title":"Visual results following cobalt plaque radiotherapy for posterior uveal melanomas","volume":"91","author":"Cruess","year":"1984","journal-title":"Ophthalmology"},{"key":"R12-20260717","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0161-6420(99)90124-0","article-title":"Palladium-103 plaque radiotherapy for choroidal melanoma: results of a 7-year study","volume":"106","author":"Finger","year":"1999","journal-title":"Ophthalmology"},{"key":"R13-20260717","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41433-022-01944-4","article-title":"Long-term visual outcomes after ruthenium plaque brachytherapy for posterior choroidal melanoma","volume":"37","author":"O'Day","year":"2023","journal-title":"Eye (Lond)"},{"key":"R14-20260717","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ophtha.2013.08.039","article-title":"Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma","volume":"121","author":"Shah","year":"2014","journal-title":"Ophthalmology"},{"key":"R15-20260717","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaophthalmol.2019.5132","article-title":"Visual outcome at 4 years following plaque radiotherapy and prophylactic intravitreal bevacizumab (every 4 months for 2 years) for uveal melanoma: Comparison with nonrandomized historical control individuals","volume":"138","author":"Shields","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R16-20260717","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/bjophthalmol-2019-314686","article-title":"Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients","volume":"104","author":"Dalvin","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R17-20260717","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/jamaophthalmol.2014.111","article-title":"Plaque radiotherapy for juxtapapillary choroidal melanoma: treatment complications and visual outcomes in 650 consecutive cases","volume":"132","author":"Sagoo","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R18-20260717","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archopht.117.5.609","article-title":"Radiation retinopathy following plaque radiotherapy of posterior uveal melanoma","volume":"117","author":"G\u00fcnd\u00fcz","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"R19-20260717","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0002-9394(98)00445-0","article-title":"Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement","volume":"127","author":"G\u00fcnd\u00fcz","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"R20-20260717","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaophthalmol.2018.3881","article-title":"Visual outcome and millimeter incremental risk of metastasis in 1780 patients with small choroidal melanoma managed by plaque radiotherapy","volume":"136","author":"Shields","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R21-20260717","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/APO.0000000000000271","article-title":"Prophylactic intravitreal bevacizumab after plaque radiotherapy for uveal melanoma: analysis of visual acuity, tumor response, and radiation complications in 1131 eyes based on patient age","volume":"9","author":"Chang","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R22-20260717","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1167\/iovs.08-1935","article-title":"Intersession repeatability of visual acuity scores in age-related macular degeneration","volume":"49","author":"Patel","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R23-20260717","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2471\/BLT.07.045120","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"85","author":"von Elm","year":"2007","journal-title":"Bull World Health Organ"},{"key":"R24-20260717","first-page":"473","article-title":"Vision and quality-of-life","volume":"97","author":"Brown","year":"1999","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R25-20260717","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0161-6420(00)00635-7","article-title":"Quality of life associated with unilateral and bilateral good vision","volume":"108","author":"Brown","year":"2001","journal-title":"Ophthalmology"},{"key":"R26-20260717","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.survophthal.2018.11.001","article-title":"Health care stakeholder perceptions of vision loss","volume":"64","author":"Brown","year":"2019","journal-title":"Surv Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:01:26Z","timestamp":1784325686000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004849"}},"subtitle":["Analysis of \u226515-Letter Visual Acuity Loss in the Pre\u2013anti-VEGF Era"],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004849","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}